Family Offices Focus on Sourcing Early Stage Assets in Europe

17 Jan

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) and the Stetson Family Office (SFO) relationship began over 18 months ago when Chuck Stetson decided that the Redefining Early Stage Investments (RESI) Conference Series was the perfect vehicle for his global family office network to achieve two of his goals. The first goal is matching the “dollars and desires” of the early stage family office investor with the vetting capability of LSN’s vast early stage angel network. The second goal was using RESI to surface the companies that needed the capital to make it through early stage development.

Chuck’s vision morphed into an official entity called the Global Family Office BioForum (GFOB), which he launched this year at RESI SF during the JP Morgan event in San Francisco. GFOB is an alliance of international family offices. This organization currently spans 18 cities in the U.S., Europe and Asia, and now has recently expanded to working in cooperation with the Angel Capital Association with 13,000 members in 260 organizations. Click to read the full press release here https://www.globalbetterhealth.org/cleveland

LSN and SFO will be bringing a GFOB delegation to the RESI Europe event March 25th in Vienna, Austria. This RESI event will be unique in that it is the first time that RESI has made an appearance in Europe, which means it will be the first time the continent has seen this type of dedicated, investor-focused, partnering event. RESI is known for being the only conference that actually delivers a one-to-one ratio of investors to fundraising CEOs and scientist-entrepreneurs. LSN expects to have 300+ early stage global investors at the RESI Europe event and with the GFOB delegation this will be the first time this many global family office investors has gathered under one roof in Europe.

Including the Stetson Family Office Global Network, RESI will feature ten categories of global investors such as VC, PE, Pharma, foundations, and angel groups. RESI caters to the earliest stage who seek seed, grants and angel capital in the range of 25K to 2mm and the early stage seeking series A and B round funding of 2-10mm. RESI is unique because it is cross silo helping fund early stage drugs, devices, diagnostics and digital health startups.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: